Eeffect of rebamipide for ESD-induce ulcer in early gastric cancer

Eeffect of rebamipide for ESD-induce ulcer in early gastric cancer - rebamipide for ESD-induce ulcer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005134

Enrollment

Registered

2011-02-24

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early gastric cancer

Interventions

8 weeks treatment of rebamipide 300mg t.i.d 8 weeks teatment of ransoprazole t.i.d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of ESD treatment for early gastric cancer

Exclusion criteria

Exclusion criteria: Exclusion criteria included patients of other ulcer drugs, or NSAIDs,or aspirin,or anticoagulants,or predonisolone.

Design outcomes

Primary

Measure	Time frame
Endoscopic examination 4 and 8 weeks after ESD	—

Secondary

Measure	Time frame
Clinical symptoms	—

Countries

Japan

Contacts

Public Contactmatsui shigenaga

Kinki university hospital gastroenterology

ma2i@med.kindai.ac.jp072-366-0221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026